PDCD1 and cancer: Based on data from patients with dMMR/MSI-H colorectal adenocarcinoma who received anti-PD-1/PD-L1 immunotherapy, researchers found that the median irPFS of patients with H. pylori-positive cancer was significantly shorter than that of H. pylori-negative patients, and the same discrepancy were observed in irOS.